Global Antibody Drug Conjugates Market Size, Share, Opportunities, And Trends By Product Type (Adcetris, Kadcyla, Other Product Types), By Target Type (Cd30 Antibodies, Her2 Antibodies, Others), By Technology (Cleavable Linker, Non-Cleavable Linker), By Application (Breast Cancer, Blood Cancer, Urinary Tract/Bladder Cancer, Cervical And Head & Neck Cancer), By End-User (Hospitals, Clinics, Others), And By Geography - Forecasts From 2024 To 2029

The global antibody drug conjugates market is anticipated to grow at a compound annual growth rate (CAGR) of 27.33% over the forecast period to reach US$36,053.494 million by 2029, increasing from US$6,644.446 million in 2022.

Antibody-drug conjugate (ADC) is an emerging anti-cancer treatment that specializes in oncology and is used to treat a variety of cancers such as lung, breast, blood, cervical, and other tumors, as well as other similar diseases. The primary components of antibody-drug conjugates are a monoclonal antibody, a linker molecule, and a cytotoxic or payload molecule that causes cancer cells to die. Using ADC antibody-drug conjugates has several advantages over other cancer treatment medications, such as chemotherapy, in that these ADC cells can specifically destroy cancer cells while sparing the patient's healthy cells.  ADCs can be used to treat cancer cells in the human body in conjunction with a few other cancer-fighting medications.

Moreover, increasing market investments are anticipated to strengthen the growth for of antibody-drug conjugates and broaden their use, contributing to the market's expansion. For instance, to provide patients with potentially life-saving cancer treatments, Axplora, a preeminent partner to Pharma companies and Biotechs for complex APIs, announced the investment of €8 million in January 2024 to increase capacity for antibody-drug conjugate payload manufacturing at its Le Mans site 

Furthermore, stress on a psychological level affects the body functions, like elevated cortisol levels, which can result in chronic inflammation and raise the risk of cancer and other illnesses. For instance, potentially modifiable risk factors, such as increased body weight, alcohol use, poor diet, and tobacco use are linked to over 40% of all cancers in the population .

Moreover, 18% of cancer survivors received their diagnosis 20 years or more ago, while 69% of survivors received their diagnosis five years or more ago. With significant variations depending on the type of cancer, only 1 in 10 survivors are younger than 50 years old, and two-thirds (67%) are 65 years of age or older. 

Moreover, clinical trials are carried out by the majority of companies in order to expand the label of their approved products and introduce new products into the market. For instance, in January 2022, patients with advanced solid tumors were enrolled in phase I clinical trials of two novel antibody-drug conjugates, SGN-B7H4V & SGN-PDL1V, by Seagen .

Furthermore, Seagen and Astellas completed patient enrollment for the cohort K EV-103 trial in April 2023, which is intended to treat first-line metastatic urothelial cancer (mUC) . Further, market growth in the market is expected to be driven by the clinical trial study's successful conclusion and the products' subsequent approval.

Rising prevalence of breast cancer is anticipated to propel market growth.

The rising incidence of breast cancer worldwide is expected to drive significant growth in the breast cancer segment over the forecast period. Over the course of the forecast period, the market is expected to grow due to the increasing number of product approvals and launches, as well as the ongoing clinical trials utilizing antibody-drug conjugates for breast cancer.

The effectiveness of ADCs antibody-drug conjugates in treating breast cancer has prompted a plethora of novel drug clinical trials, which will probably accelerate the market's expansion. For instance, the most promising new antibody-drug conjugates, which seem to be the TROP2-directed datopotamab deruxtecan, have demonstrated encouraging early-phase activity in advanced relapsed/refractory HER2-negative breast cancer. 

Moreover, the demand for this medication is rising due to the recent approvals and introductions of antibody-drug conjugates for breast cancers, which is expected to accelerate the segment's growth during the study period. For instance, the United States Food and Drug Administration (FDA) approved Trodelvy in February 2023 for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer that is unresectable locally advanced or metastatic and who have received endocrine-based therapy and at least two more systemic therapies in the metastatic setting.

The Adcetris market is expected to grow

Adcetris is a prescription antibody-drug conjugate (ADC) used to treat adults with Hodgkin lymphoma, certain T-cell lymphomas as well as other cancers. The drug specifically targets CD30, a protein located on the surface of cells. Adcetris is available in more than 75 countries and is developed and commercialized by Seattle Genetics Inc. in collaboration with Takeda Pharmaceutical Company Limited, globally. It received approval from the U.S. Food and Drug Administration (FDA) in 2011. Currently, it is approved in a total of six indications to treat Hodgkin lymphoma and T-cell lymphomas in various settings including as frontline therapy. Adcetris is the first in a new generation of ADCs, prior to its approval of it the standard of care frontline therapy for patients with Hodgkin lymphoma and PTCL was seen.

The chart shows data from Seattle Genetics Inc., Annual report, the total revenue of adcetris in nine months ended September 30.2023 were $1,583 million in the year 2023 from $ 1,243 million in the year 2022 which shows an increase of 27%.  The mode of electronic communication was highly adopted by the company’s on-field-based personnel to communicate about the product to the healthcare workers.

Further, in accordance with local and national protocols adopted by the countries, on-field, face-to-face interactions were done. This flexible adoption clearly helped the sales of Adcetris during the pandemic. In addition, increasing, research and development along with rising cancer rates will be propelling the its demand for Adcetris in the coming years. For instance, in march 2024, Pfizer conducted a Phase 3 trial of ADCETRIS® regimen in combination with lenalidomide and rituximab for treating relapsed/refractory diffuse large B-cell lymphoma. The study showed a significant improvement in overall survival compared to lenalidomide and rituximab plus placebo, as well as positive outcomes in secondary endpoints

The market is projected to grow in the North American region.

The market for antibody drug conjugates has seen substantial expansion in United States over the years, making it one of the fastest growing in the area. The rising incidence of cancer, growing elderly population, and increasing investments in R&D activities for the discovery of novel treatments are driving the expansion of the USA antibody drug conjugates market.

In 2020, the population of people aged 65 and up in the United States totaled 54.1 million accounting for one out of every seven Americans. According to the Administration for Community Living Administration's 2020 Profile of Older Americans, those aged 65 and older made up 16 percent of the population in 2019, predicted to rise to 21.6 percent by 2040.  

In addition, the government's strong support in the form of funding, clinical trials, and United States Food and Drug Administration (FDA) approvals are projected to propel the ADC market forward at a rapid pace.

Further Trodelvy, an antibody-drug conjugate, was first approved by the FDA for accelerated marketing in April 2020 for locally advanced triple-negative breast cancer (TNBC) that has received two or more systemic treatments. In April 2021, the FDA fully approved Trodelvy for the treatment of TNBC. Sutro Biopharma acquired Fast Track designation for its ADC named “STRO-002” in September 2021 from the FDA, which targets patients with platinum-resistant epithelial ovarian, primary peritoneal cancer, or fallopian tube who have received one to three lines of systemic therapy in the past.

The growing cases of fatal cancers in the adult population in the United States are expected to boost the demand and urgency for developing antibody-drug conjugates and the rising need for therapies. According to the American Cancer Society's publication Cancer Facts and Figures 2022, there will likely be 1.918 million new cancer cases identified in the country with 609,360 estimated deaths in 2022.  It also predicts that in 2023, the US experienced 1,958,310 new cancer cases and 609,820 deaths, based on data from central cancer registries and the National Center for Health Statistics, indicating a significant increase in cancer occurrence and outcomes .

Further, according to the National Cancer Institute, the most common types of cancers in 2023 are breast cancer (in women), prostate cancer, lung and bronchus, and bladder cancer among other common cancers.

Key Market Developments:

• March 2023, Ambrx Biopharma Inc. announced an interim analysis for ACE-Breast-02, a randomized Phase 3 breast cancer clinical trial that examines Ambrx's anti-HER2 antibody drug conjugate (ADC), ARX788, that has demonstrated a greater benefit in progression free survival (PFS) when compared to the active control. Humanized anti-HER2 monoclonal antibody-AS269 conjugate (ARX788) is being tested in ACE-Breast-02, a randomized, controlled pivotal Phase 3 clinical trial, to treat HER2 positive patients with locally advanced or metastatic breast cancers in China.
• Mersana Therapeutics has announced a research collaboration and license agreement with Janssen Biotech, a subsidiary of Johnson & Johnson, to develop novel antibody-drug conjugates (ADCs) for three unmet medical needs, including cancer. The collaboration aims to discover novel ADCs for three targets, facilitated by Johnson & Johnson Innovation. 
• Februray 2023, Corbus Pharmaceuticals signed an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd for the development and commercialization of CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate targeting Nectin-4. The agreement covers exclusive commercialization rights in the region including US and Canada.

Key Players:

• AstraZeneca is a key player in the global antibody drug conjugates market, renowned for its innovative oncology treatments. With a robust pipeline and strategic collaborations, AstraZeneca leverages ADC technology to develop targeted therapies, enhancing cancer treatment efficacy while minimizing side effects. Its commitment to research and development ensures a steady stream of ADC products, contributing significantly to advancing cancer care worldwide.
• Pfizer Inc. (in collaboration with Seagen, Inc.) stands at the forefront of the global antibody drug conjugates market. Leveraging Pfizer's expertise in pharmaceuticals and Seagen's proficiency in ADC technology, the collaboration yields groundbreaking therapies for various cancers. By combining targeted antibodies with potent cytotoxic agents, Pfizer and Seagen deliver innovative ADC treatments, underscoring their commitment to improving patient outcomes and addressing unmet medical needs in oncology.
• Sanofi S.A. is a prominent player in the global antibody drug conjugates market, distinguished by its commitment to innovation and patient-centric approach. Leveraging its extensive experience in pharmaceuticals and biotechnology, Sanofi pioneers the development of ADC therapies for oncology indications. With a diversified portfolio and strategic partnerships, Sanofi focuses on addressing the complexities of cancer treatment by delivering targeted therapies that offer improved efficacy and tolerability, thereby enhancing the quality of life for patients worldwide.

Global Antibody Drug Conjugates Market Scope:

Segmentation:

• By Product Type:
  • Adcetris
  • Kadcyla
  • Other Product Types
• By Target Type:
  • Cd30 Antibiotics
  • Her2 Antibiotics
  • Others
• By Technology
  • Cleavable Linker
  • Non-Cleavable Linker
• By Application
  • Breast Cancer
  • Blood Cancer
  • Urinary Tract/Bladder Cancer
  • Cervical and Head & Neck Cancer
• By End-User
  • Hospitals
  • Clinics
  • Others
• By Geography
  • North America
    • USA
    • Canada              
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others